Trial Profile

A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTX-471 (Primary)
Indications Neuroendocrine carcinoma; Neuroendocrine tumours
Focus Adverse reactions; Biomarker; Therapeutic Use
Sponsors Compass Therapeutics

Most Recent Events

06 Aug 2026 According to Compass Therapeutics media release, the trial will be initiated in Q3 2026.
05 May 2026 According to Compass Therapeutics media release, the trial is expected to initiate in second half of 2026.
05 Mar 2026 According to Compass Therapeutics media release, the trial is expected to initiate in mid-2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com